Skip to content

Are Corneal Epithelial Defects Related to Changes in Ocular Bacterial Flora in Patients With ANLDO

To Estimate Whether Corneal Epithelial Defects Occur in Patients With Acquired Nasolacrimal Duct Obstructions is Linked to Changes Occurring Within Ocular Bacterial Flora in These Patients, and What Are the Specific Changes in Their Flora.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02234700
Acronym
ANLDO
Enrollment
60
Registered
2014-09-09
Start date
2014-08-31
Completion date
2015-02-28
Last updated
2014-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Nasolacrimal Duct Obstruction

Brief summary

Comparison between patients with nasolacrimal duct obstruction and healthy patients and the influence of their bacterial flora on the corneal epithelium.

Detailed description

Any patient with nasolacrimal duct obstruction above the age of 18 Comparing changes in their bacterial ocular flora to healthy patients without obstruction and above 18 years of age

Interventions

None listed

Sponsors

Western Galilee Hospital-Nahariya
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years of age or older, nasolacrimal duct obstruction

Exclusion criteria

* younger then 18 years of age * ocular infections * patients after repair of lacrimal duct surgery * systemic active diseases * patients taking medication that are know to influence bacterial flora of the eye

Design outcomes

Primary

MeasureTime frameDescription
the change of ocular normal flora in patients with nasolacrimal duct obstruction as a comparison to general population.6 monthas the literature suggests most of the ocular flora is composed of Staphylococcus and Haemophilus, any change in these composition will be considered abnormal.

Countries

Israel

Contacts

Primary Contactabdelhakim Ayub, MD
abedayub@gmail.com0502999110

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026